Published December 2023
| Version v1
Journal article
Management of 80 sinonasal undifferentiated carcinomas. Retrospective multicentre study of the French Network of Rare Head and Neck Cancers (REFCOR)
Creators
- Pouvreau, Pierre
- Coelho, Julien
- Rumeau, Cécile
- Malard, Olivier
- Garrel, Renaud
- Michel, Justin
- Righini, Christian
- Vergez, Sebastien
- Baudouin, Robin
- Bastit, Vianney
- Marie, Jean-Paul
- Villepelet, Aude
- Moya-Plana, Antoine
- Philouze, Pierre
- Saroul, Nicolas
- Digue, Laurence
- Daste, Amaury
- Renard, Sophie
- Moriniere, Sylvain
- Carsuzaa, Florent
- Verillaud, Benjamin
- Poissonnet, Gilles
- Schultz, Philippe
- Brenet, Esteban
- Mouawad, François
- Thariat, Juliette
- Vulquin, Noémie
- Castain, Claire
- de Gabory, Ludovic
- Dupin, Charles
Contributors
Others:
- Université de Bordeaux (UB)
- Sommeil, Addiction et Neuropsychiatrie [Bordeaux] (SANPSY) ; Université de Bordeaux (UB)-CHU de Bordeaux Pellegrin [Bordeaux]-Centre National de la Recherche Scientifique (CNRS)
- Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)
- Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)
- CHU Montpellier = Montpellier University Hospital ; Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
- Hôpital de la Conception [CHU - APHM] (LA CONCEPTION)
- Centre Hospitalier Universitaire [CHU Grenoble] (CHUGA)
- Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
- Hôpital Foch [Suresnes]
- CHU Caen ; Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)
- CHU Rouen ; Normandie Université (NU)
- Centre Hospitalier Intercommunal de Créteil (CHIC)
- Institut Gustave Roussy (IGR)
- Hospices Civils de Lyon (HCL)
- CHU Clermont-Ferrand
- Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux)
- CHU Trousseau [Tours] ; Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)
- Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers [La Milétrie])
- Hôpital Lariboisière-Fernand-Widal [APHP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL) ; UNICANCER-Université Côte d'Azur (UniCA)
- Université de Strasbourg (UNISTRA)
- Hôpital universitaire Robert Debré [Reims] (CHU Reims)
- Centre Hospitalier Régional Universitaire [CHU Lille] (CHRU Lille)
- Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC) ; Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)
- Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL) ; UNICANCER
- CHU de Bordeaux Pellegrin [Bordeaux]
Description
Objectives: Sinonasal undifferentiated carcinoma (SNUC) is a rare and aggressive disease requiring multimodal treatment, and multiple new entities once included in the spectrum of SNUC, such as SWI/SNF-deficient carcinomas, are emerging. We aimed to provide new data regarding the role of chemotherapy and surgery and the prognostic factors of disease-free survival.Methods: This study was based on data from the REFCOR database and included patients with SNUC treated with curative intent from 2007 to 2021 across 22 centres in France.Results: A total of 80 patients were included in the analysis. Among the entire cohort, the 5-year disease-free survival (DFS) and overall survival (OS) rates were 58% and 63%, respectively. Of 100% of the patients treated with irradiation, 29% underwent surgery, 56% neoadjuvant chemotherapy (82% had either a partial or a complete response) and 76% chemoradiotherapy. No treatment modality was associated with a better OS or DFS, including surgery (p = 0.34). There was a trend for a better DFS for the patients treated with chemotherapy (neoadjuvant or concomitant, p = 0.062). Overall survival at 3 years was 58% for SWI/SNF deficient group and 86% for non deficient group (p = 0.14). The locoregional relapse rate without distant metastases was 21% in the exclusive radiotherapy group and 26% in the surgery group. Grade 3 or higher toxicities concerned 9%, 32% and 29% of patients for surgery, radiotherapy and chemotherapy respectively.Conclusion: In the management of localised SNUC among all patients treated with irradiation, surgery yielded no benefit, whereas the addition of chemotherapy tended to improve disease-free survival.
Abstract
International audienceAdditional details
Identifiers
- URL
- https://hal.science/hal-05003528
- URN
- urn:oai:HAL:hal-05003528v1
Origin repository
- Origin repository
- UNICA